2021 MIPS Measure #410: Psoriasis: Clinical Response to Systemic Medications 

Measure Type High Priority Measure? Collection Type(s)
Outcome yes Medicare Part B Claims, MIPS CQM


Measure Description

Percentage of psoriasis vulgaris patients receiving systemic medication who meet minimal physician-or patient-reported disease activity levels. It is implied that establishment and maintenance of an established minimum level of disease control as measured by physician-and/or patient-reported outcomes will increase patient satisfaction with and adherence to treatment